Post-partum depression drug trial gives Sage Therapeutics a boost

Shares of Cambridge’s Sage Therapeutics rose more than 14 percent Tuesday morning after positive data from a small trial of a post-partum depression drug.

The company reported that four women with severe depression after childbirth made complete recoveries within 60 hours of being treated with SAGE-547, an experimental drug that also is being tested to treat a seizure disorder. Sage’s stock rose 14.7 percent by midmorning, hitting $86.20.

Sage said the trial was conducted without a comparison group, and said it was ended earlier than expected because of the positive results from the first four subjects. The drugmaker said it plans to conduct controlled clinical trials as soon as possible.


The price of the drug researcher’s stock has more than doubled since its initial public offering last summer. Its lead drug candidate, SAGE-547, is entering phase 3 clinical trials for the treatment of a rare disorder called SRSE.

Jack Newsham can be reached at jack.newsham@globe.com. Follow him on Twitter @TheNewsHam.